InnoCare Pharma Ltd. (09969.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 15.15

From 52W high−23.35%

Volume9.38M

Market capHKD 25.92B

P/E (TTM)24.2x

P/S (TTM)8.0x

Div yield—

Key dataSep 18, 2026

Open

HKD 15.15

From 52W high

−23.35%

Volume

9.38M

Market cap

HKD 25.92B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

18.6x

P/E (TTM)

24.2x

RSI (14)

51.4

MomentumView details →

1D Return

−2.52%

YTD Return

+19.59%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

24.2x

EV/EBITDA

18.6x

EV/Sales

5.8x

P/S (TTM)

8.0x

P/B (TTM)

2.9x

ProfitabilityView details →

Gross Margin

89.85%

Net Margin

32.94%

EBITDA Margin

31.32%

ROE (TTM)

11.83%

ROA (TTM)

8.09%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+108.49%

EPS YoY

+479.61%

FCF YoY

+222.38%

Revenue CAGR 3Y

+54.30%

EPS CAGR 3Y

+238.46%

EBITDA YoY

+410.37%

MomentumView details →

1D Return

−2.52%

YTD Return

+19.59%

1Y Return

−10.52%

RSI (14)

51.4

vs 50D SMA

+2.09%

vs 200D SMA

+11.82%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

4.21x

Quick Ratio

4.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

−12.82%

Financials snapshotView financials →

Revenue (TTM)

2.75B

Net Income (TTM)

907.26M

Op. CF (TTM)

320.62M

Next earningsNov 16, 2026 →

Latest newsMore news →

Innolux Corporation is restructuring its factories, with its second plant scheduled to close in September 2026, prompting subsidiary InnoCare Optoelectronics to prepare for a major supply-chain adjustment.9d ago

Innocare Pharma announced that its self-developed bispecific antibody-drug conjugate ICP-B381 targeting PSMA and STEAP1 received clinical trial approval from China's NMPA CDE for treating solid tumors including prostate cancer, marking the company's first bispecific ADC and third ADC candidate to enter clinical development.12d ago

Similar companies

Royalty Pharma plcRPRX Insmed IncorporatedINSM Incyte CorporationINCY Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 特宝生物688278.SH BioNTech SEBNTX Find similar companies →

Latest newsMore news →

Innolux Corporation is restructuring its factories, with its second plant scheduled to close in September 2026, prompting subsidiary InnoCare Optoelectronics to prepare for a major supply-chain adjustment.9d ago Innocare Pharma announced that its self-developed bispecific antibody-drug conjugate ICP-B381 targeting PSMA and STEAP1 received clinical trial approval from China's NMPA CDE for treating solid tumors including prostate cancer, marking the company's first bispecific ADC and third ADC candidate to enter clinical development.12d ago